Safety and efficacy of Certolizumab Pegol in a real-life cohort of patients with Psoriasis and Psoriatic Arthritis.
CONCLUSIONS: CZP was safe and effective in a real-life cohort of patients affected by PsO and PsA, who have had an inadequate response to previous systemic treatments.
PMID: 30963798 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Arthritis | Dermatology | Laboratory Medicine | Methotrexate | Pain | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Statistics | Study